Notably, Tazemetostat, an oral EZH2 inhibitor, has demonstrated favorable tolerability in older patients with advanced solid tumors, including those with genitourinary malignancies (e.g., prostate cancer) (Izutsu et al., 2021). This evidence concerns the gene EZH2 and prostate carcinoma.